Skip to content

Home
Insights
Brochures
Careers
About us
News

Home
Insights
Brochures
Careers
About us
News

Pharma News

Highlights from the Week of 02 February 2026 - 09 February 2026 ( FDA, Approval ) FDA approves Exelixis' zanzalintinib in combination with atezolizumab for the treatment of adult patients with previously treated metastatic colorectal cancer, with a PDUFA date of December 3, 2026 ( EU, Approval ) The European Commission approves GSK's NUCALA as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease based on the data from Phase III MATINEE trial ( NMPA, Approval ) NMPA approves Bayer's NUBEQA in combination with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer based on the Phase III ARANOTE trial ( NMPA, Approval ) NMPA approves a new indication of Kelun-Biotech's sacituzumab tirumotecan to treat unresectable or metastatic HR+/HER2- breast cancer who previously received endocrine therapy and at least one line of chemotherapy Pg 1/3 All logos and trademarks remain the intellectual properties of their respective owners

📢Highlights from the Week of 02 February 2026 – 09 February 2026 in the world of pharma and healthcare! 🗞️👀

February 9, 2026

Highlights from the week of 19 January - 26 January Ionis Pharmaceuticals ( EU, Approval ) European Commission approves Ionis and Otsuka's DAWNZERA for the prevention of recurrent hereditary angioedema attacks in patients aged 12 years and older GSK ( EU, Approval ) GSK’s vaccine, AREXVY, receives European Commission approval for expanded use in adults aged 18 years and older to prevent lower respiratory tract disease caused by RSV GSK ( NMPA, Approval ) NMPA approves GSK's TRELEGY ELLIPTA as the first and only single inhaler triple therapy for the maintenance treatment of both asthma and chronic obstructive pulmonary disease in adults Akesobio ( NMPA, Approval ) Akeso gains NMPA approval for its sNDA AK-111, a monoclonal antibody, to treat active ankylosing spondylitis All logos and trademarks remain the intellectual properties of their respective owners

📢Highlights from the Week of 19th January – 26th January in the world of pharma and healthcare! 🗞️👀

January 27, 2026

pharma Business Intelligence & Strategic Consulting

📢Highlights from the Week of 1st January 2026 to 12th January 2026 in the world of pharma and healthcare! 🗞️👀

January 13, 2026

« Previous Page1 Page2 Page3 Page4 Page5 Next »

Investor calendar

Q4 2025 Earning conference Call Jan 28,2025 To Jan 30,2025 Jan 28 Jan 29 Jan 30 All logos and trademarks remain the intellectual properties of their respective owners

📢 Attention ⏰ Stay up to date with the latest investor calls by checking out our calendar for the week of Jan 28,2026 To Jan 30,2026 💻

January 27, 2026

44th Annual J.P. Morgan Healthcare Conference Jan 12,2026 To Jan 14,2026 Jan 12 Jan 13 Jan 14 All logos and trademarks remain the intellectual properties of their respective owners

📢 Attention ⏰ Stay up to date with the latest investor calls by checking out our calendar for the week of Jan 12,2026 To Jan 14,2026 💻

January 13, 2026

Pfizer Analyst and Investor Call to Review Pfizer Full-Year 2026 Financial Guidance 16th December, 2025 Dec 16 Pfizer Visit our website for more updates | www.vyuhpharma.com All logos and trademarks remain the intellectual properties of their respective owners

📢 Attention ⏰ Stay up to date with the latest investor calls by checking out our calendar for the week of16th December, 2025 💻

December 16, 2025

« Previous Page1 Page2 Page3 Page4 Page5 Next »

Healthcare Insights

The Pharma BI division of

Vyuhgenics Inc.

Henderson, Nevada, USA – 89014

Vyuhpharma ®, All Rights Reserved.

Sitemap

Terms of use

Connect with us

Please fill in the information below, and we'll get back to you.

Full Name

Email Address

Your Company

Contact

Your message